Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase

Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase

<p>Abstract</p> <p>Background</p> <p>Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to these d...

Full description

Bibliographic Details
Main Authors:	Christensen Mette K, Imai Shin-Ichiro, Yoshino Jun, Kiess Wieland, Garten Antje, Petersen Jakob G, Olesen Uffe H, Fristrup Peter, Thougaard Annemette V, Björkling Fredrik, Jensen Peter B, Nielsen Søren J, Sehested Maxwell
Format:	Article
Language:	English
Published:	BMC 2010-12-01
Series:	BMC Cancer
Online Access:	http://www.biomedcentral.com/1471-2407/10/677

Similar Items

Structural Basis of Beneficial Design for Effective Nicotinamide Phosphoribosyltransferase Inhibitors
by: Sei-ichi Tanuma, et al.
Published: (2020-08-01)

Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies
by: Paulina Biniecka, et al.
Published: (2023-02-01)

Extracellular nicotinamide phosphoribosyltransferase: role in disease pathophysiology and as a biomarker
by: Elise Semerena, et al.
Published: (2023-10-01)

Nicotinamide phosphoribosyltransferase may be involved in age-related brain diseases.
by: Li-Ying Liu, et al.
Published: (2012-01-01)

Nicotinamide phosphoribosyltransferase as a biomarker for the diagnosis of infectious pleural effusions
by: Jing Huang, et al.
Published: (2021-10-01)

Extracellular Nicotinamide Phosphoribosyltransferase Is a Therapeutic Target in Experimental Necrotizing Enterocolitis
by: Melissa D. Halpern, et al.
Published: (2024-04-01)

Immunohistochemical Analysis of Nicotinamide Phosphoribosyltransferase Expression in Gastric and Esophageal Adenocarcinoma (AEG)
by: Alexander Arnold, et al.
Published: (2022-12-01)

Epigenetic regulation of Runx2 transcription and osteoblast differentiation by nicotinamide phosphoribosyltransferase
by: Min Ling, et al.
Published: (2017-05-01)

Extracellular Nicotinamide Phosphoribosyltransferase Is a Component of the Senescence-Associated Secretory Phenotype
by: Chisaka Kuehnemann, et al.
Published: (2022-07-01)

Clickable prodrugs bearing potent and hydrolytically cleavable nicotinamide phosphoribosyltransferase inhibitors
by: Sadrerafi K, et al.
Published: (2018-04-01)

Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy
by: Peter M LoCoco, et al.
Published: (2017-11-01)

Nicotinamide Phosphoribosyltransferase Acetylation Mediating Muscle Dysfunction Contributes to Sleep Apnoea in Obesity
by: Liu Zhang, et al.
Published: (2025-02-01)

Iminosugar-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Potential Anti-Pancreatic Cancer Agents
by: Irene Conforti, et al.
Published: (2023-05-01)

Serum nicotinamide phosphoribosyltransferase as a novel biomarker for non-traumatic osteonecrosis of the femoral head
by: Shiying Wang, et al.
Published: (2022-11-01)

Cerebral ischemia is exacerbated by extracellular nicotinamide phosphoribosyltransferase via a non-enzymatic mechanism.
by: Bing Zhao, et al.
Published: (2013-01-01)

Metabolomics analysis of metabolic effects of nicotinamide phosphoribosyltransferase (NAMPT) inhibition on human cancer cells.
by: Vladimir Tolstikov, et al.
Published: (2014-01-01)

The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells
by: Lan Dan, et al.
Published: (2012-04-01)

Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancer
by: Mario Paolo Colombo, et al.
Published: (2023-10-01)

Nicotinamide Phosphoribosyltransferase‐elevated NAD+ biosynthesis prevents muscle disuse atrophy by reversing mitochondrial dysfunction
by: Yao Zhang, et al.
Published: (2023-04-01)

Extracellular nicotinamide phosphoribosyltransferase boosts IFNγ-induced macrophage polarization independently of TLR4
by: Giorgia Colombo, et al.
Published: (2022-04-01)

Nicotinamide phosphoribosyltransferase expression and clinical outcome of resected stage I/II pancreatic ductal adenocarcinoma.
by: Katelynn Davis, et al.
Published: (2019-01-01)

Targeting of nicotinamide phosphoribosyltransferase enzymatic activity ameliorates lung damage induced by ischemia/reperfusion in rats
by: Geng-Chin Wu, et al.
Published: (2017-04-01)

1341 Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancer
by: Mario Paolo Colombo, et al.
Published: (2023-11-01)

Correction: Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancer
Published: (2024-01-01)

A Humanized Monoclonal Antibody Targeting Extracellular Nicotinamide Phosphoribosyltransferase Prevents Aggressive Prostate Cancer Progression
by: Belinda L. Sun, et al.
Published: (2021-12-01)

Exercise training upregulates intracellular nicotinamide phosphoribosyltransferase expression in humans: a systematic review with meta-analysis
by: Xu Sun, et al.
Published: (2023-10-01)

Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity.
by: Susana Vallejo, et al.
Published: (2011-01-01)

Role of secreted extracellular nicotinamide phosphoribosyltransferase (eNAMPT) in prostate cancer progression: Novel biomarker and therapeutic target
by: Belinda L Sun, et al.
Published: (2020-11-01)

Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD.
by: Nathalie Busso, et al.
Published: (2008-01-01)

Suppression of nicotinamide phosphoribosyltransferase expression by miR-154 reduces the viability of breast cancer cells and increases their susceptibility to doxorubicin
by: Zahra Bolandghamat Pour, et al.
Published: (2019-11-01)

Nicotinamide Phosphoribosyltransferase Knockdown Leads To Lipid Accumulation In HepG2 Cells Through The SIRT1-AMPK Pathway
by: Davod Ilbeigi, et al.
Published: (2020-09-01)

[18F]FLT PET for non-invasive assessment of tumor sensitivity to chemotherapy: studies with experimental chemotherapy TP202377 in human cancer xenografts in mice.
by: Mette Munk Jensen, et al.
Published: (2012-01-01)

Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice.
by: Mette Munk Jensen, et al.
Published: (2010-01-01)

Astrocyte-derived exosomal nicotinamide phosphoribosyltransferase (Nampt) ameliorates ischemic stroke injury by targeting AMPK/mTOR signaling to induce autophagy
by: Yang Deng, et al.
Published: (2022-12-01)

A Nicotinamide Phosphoribosyltransferase Inhibitor, FK866, Suppresses the Growth of Anaplastic Meningiomas and Inhibits Immune Checkpoint Expression by Regulating STAT1
by: Yuxuan Deng, et al.
Published: (2022-04-01)

Nicotinamide Phosphoribosyltransferase Inhibitor APO866 Prevents IL-1β-Induced Human Nucleus Pulposus Cell Degeneration via Autophagy
by: Changgui Shi, et al.
Published: (2018-09-01)

Nicotinamide riboside kinases display redundancy in mediating nicotinamide mononucleotide and nicotinamide riboside metabolism in skeletal muscle cells
by: Rachel S. Fletcher, et al.
Published: (2017-08-01)

Associations between Tissue Visfatin/Nicotinamide, Phosphoribosyltransferase (Nampt), Retinol Binding Protein-4, and Vaspin Concentrations and Insulin Resistance in Morbidly Obese Subjects
by: Zeynep Goktas, et al.
Published: (2013-01-01)

Oxidative stress induces cell death partially by decreasing both mRNA and protein levels of nicotinamide phosphoribosyltransferase in differentiated PC12 cells
by: Cuiyan Zhou, et al.
Published: (2021-05-01)

The Cytokine Nicotinamide Phosphoribosyltransferase (eNAMPT; PBEF; Visfatin) Acts as a Natural Antagonist of C-C Chemokine Receptor Type 5 (CCR5)
by: Simone Torretta, et al.
Published: (2020-02-01)